

## WHAT IS CLAIMED IS:

1. Use of COR-001 for the manufacture of a medicament for reducing the risk of cardiovascular morbidity and mortality in a patient with inflammation that has KDOQI stage 3-5 chronic kidney disease and a CRP level greater than 2 mg/L, wherein COR-001 is administered at a dose of 5-30 mg subcutaneously once a month, wherein the dose is sufficient to reduce the CRP level to 2 mg/L or less and does not cause a decrease in absolute neutrophil count (ANC) below 1,500 cells/ $\mu$ L.
2. Use of COR-001 according to claim 1, wherein COR-001 is administered at a dose of 10-20 mg subcutaneously once a month.
3. Use of COR-001 according to claim 1, wherein COR-001 is administered at a dose of 15 mg subcutaneously once a month.
4. Use of COR-001 according to any one of claims 1 to 3, wherein the administration reduces the risk of heart failure and/or cardiovascular death.
5. Use of COR-001 according to any one of claims 1 to 3, wherein the cardiovascular morbidity and mortality is selected from a group consisting of (i) nonfatal myocardial infarction, (ii) nonfatal stroke, and (iii) cardiovascular death.
6. Use of COR-001 according to any one of claims 1 to 3, wherein the cardiovascular morbidity and mortality is heart failure.

- ~~1. — A method for treating IL-6 mediated inflammation in a patient, comprising:  
administering an IL-6 antagonist to a patient with IL-6 mediated inflammation at a dose that is sufficient to reduce inflammation without causing immune suppression.~~
- ~~2. — The method of claim 1, wherein the patient has an elevated pre-treatment C-reactive protein (CRP) level.~~
- ~~3. — The method of claim 2, wherein the pre-treatment CRP level of the patient is at least 2 mg/L.~~

- ~~4. — The method of claim 3, wherein the pre-treatment CRP level of the patient is at least 4 mg/L.~~
- ~~5. — The method of claim 4, wherein the pre-treatment CRP level of the patient is at least 6 mg/L.~~
- ~~6. — The method of claim 5, wherein the pre-treatment CRP level of the patient is at least 10 mg/L.~~
- ~~7. — The method of any of the above claims, wherein the patient has an elevated pre-treatment serum IL-6 level.~~
- ~~8. — The method of claim 7, wherein the pre-treatment serum IL-6 level of the patient is at least 2 pg/mL.~~
- ~~9. — The method of claim 8, wherein the pre-treatment serum IL-6 level of the patient is at least 4 pg/mL.~~
- ~~10. — The method of claim 9, wherein the pre-treatment serum IL-6 level of the patient is at least 5 pg/mL.~~
- ~~11. — The method of claim 10, wherein the pre-treatment serum IL-6 level of the patient is at least 10 pg/mL.~~
- ~~12. — The method of any of the above claims, wherein the inflammation is measured by the level of C reactive protein (CRP).~~
- ~~13. — The method of claim 12, wherein the post-treatment CRP level is no more than 2 mg/L.~~
- ~~14. — The method of claim 13, wherein the post-treatment CRP level is no more than 1 mg/L.~~
- ~~15. — The method of claim 12, wherein the CRP level is decreased by at least 50% as compared to pre-treatment levels.~~
- ~~16. — The method of claim 15, wherein the CRP level is decreased by at least 70% as compared to pre-treatment levels.~~
- ~~17. — The method of claim 16, wherein the CRP level is decreased by at least 80% as compared to pre-treatment levels.~~
- ~~18. — The method of claim 17, wherein the CRP level is decreased by at least 90% as compared to pre-treatment levels.~~

- ~~19.~~—The method of any of the above claims, wherein the immune suppression is measured by absolute neutrophil count (ANC).
- ~~20.~~—The method of claim 19, wherein the post treatment ANC is at least 500 cells/ $\mu$ L.
- ~~21.~~—The method of claim 20, wherein the post treatment ANC is at least 1000 cells/ $\mu$ L.
- ~~22.~~—The method of claim 21, wherein the post treatment ANC is at least 1500 cells/ $\mu$ L.
- ~~23.~~—The method of claim 21, wherein the post treatment ANC is at least 2000 cells/ $\mu$ L.
- ~~24.~~—The method of claim 19, wherein the ANC is decreased by no more than 2000 cells/ $\mu$ L as compared to pre treatment levels.
- ~~25.~~—The method of claim 24, wherein the ANC is decreased by no more than 1500 cells/ $\mu$ L as compared to pre treatment levels.
- ~~26.~~—The method of claim 25, wherein the ANC is decreased by no more than 1000 cells/ $\mu$ L as compared to pre treatment levels.
- ~~27.~~—The method of claim 26, wherein the ANC is decreased by no more than 500 cells/ $\mu$ L as compared to pre treatment levels.
- ~~28.~~—The method of claim 19, wherein the ANC is decreased by no more than 50% as compared to pre treatment levels.
- ~~29.~~—The method of claim 28, wherein the ANC is decreased by no more than 40% as compared to pre treatment levels.
- ~~30.~~—The method of claim 29, wherein the ANC is decreased by no more than 30% as compared to pre treatment levels.
- ~~31.~~—The method of claim 30, wherein the ANC is decreased by no more than 20% as compared to pre treatment levels.
- ~~32.~~—The method of claim 31, wherein the ANC is decreased by no more than 10% as compared to pre treatment levels.
- ~~33.~~—The method of claim 19, wherein the ANC is not decreased as compared to pre treatment levels.
- ~~34.~~—The method of any of the above claims, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

- ~~35. — The method of claim 34, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~36. — The method of claim 35, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~37. — The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 25% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~38. — The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 20% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~39. — The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 15% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~40. — The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 10% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~41. — The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 5% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.~~
- ~~42. — The method of any of the above claims, wherein the IL-6 antagonist is an anti IL-6 antibody.~~
- ~~43. — The method of claim 42, wherein the anti IL-6 antibody is COR-001.~~
- ~~44. — The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of 2–40 mg.~~
- ~~45. — The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 2 mg.~~
- ~~46. — The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 4 mg.~~

- ~~47.~~—The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 6 mg.
- ~~48.~~—The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 10 mg.
- ~~49.~~—The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 20 mg.
- ~~50.~~—The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 40 mg.
- ~~51.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of 3-70 mg.
- ~~52.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 3 mg.
- ~~53.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 7 mg.
- ~~54.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 10 mg.
- ~~55.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 17 mg.
- ~~56.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 35 mg.
- ~~57.~~—The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 70 mg.
- ~~58.~~—The method of claim 42, wherein the anti-IL-6 antibody is siltuximab.
- ~~59.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of 50-500 mg.
- ~~60.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 50 mg.
- ~~61.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 100 mg.

- ~~62.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 150 mg.
- ~~63.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 200 mg.
- ~~64.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 300 mg.
- ~~65.~~—The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 500 mg.
- ~~66.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of 80-800 mg.
- ~~67.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
- ~~68.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 160 mg.
- ~~69.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 240 mg.
- ~~70.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 320 mg.
- ~~71.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 480 mg.
- ~~72.~~—The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 800 mg.
- ~~73.~~—The method of claim 42, wherein the anti-IL-6 antibody is gerilimumab.
- ~~74.~~—The method of claim 73, wherein gerilimumab is administered intravenously at a monthly equivalent dose of 0.075-1.8 mg.
- ~~75.~~—The method of claim 73, wherein gerilimumab is administered intravenously at a monthly equivalent dose of about 0.075 mg.
- ~~76.~~—The method of claim 73, wherein gerilimumab is administered intravenously at a monthly equivalent dose of about 0.12 mg.

- ~~77.~~—The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.3 mg.
- ~~78.~~—The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.6 mg.
- ~~79.~~—The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.9 mg.
- ~~80.~~—The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 1.8 mg.
- ~~81.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of 0.125–3 mg.
- ~~82.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.125 mg.
- ~~83.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.2 mg.
- ~~84.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.5 mg.
- ~~85.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 1 mg.
- ~~86.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 1.5 mg.
- ~~87.~~—The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 3 mg.
- ~~88.~~—The method of claim 42, wherein the anti-IL-6 antibody is sirukumab.
- ~~89.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of 1.5–60 mg.
- ~~90.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 1.5 mg.
- ~~91.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 3 mg.

- ~~92.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 6 mg.
- ~~93.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 12 mg.
- ~~94.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 36 mg.
- ~~95.~~—The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- ~~96.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of 2.5–100 mg.
- ~~97.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 2.5 mg.
- ~~98.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 5 mg.
- ~~99.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
- ~~100.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
- ~~101.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 60 mg.
- ~~102.~~—The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- ~~103.~~—The method of claim 42, wherein the anti-IL-6 antibody is clazakizumab.
- ~~104.~~—The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of 3–60 mg.
- ~~105.~~—The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 3 mg.
- ~~106.~~—The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 6 mg.

- ~~107.~~—The method of claim 103, wherein elazakizumab is administered intravenously at a monthly equivalent dose of about 12 mg.
- ~~108.~~—The method of claim 103, wherein elazakizumab is administered intravenously at a monthly equivalent dose of about 24 mg.
- ~~109.~~—The method of claim 103, wherein elazakizumab is administered intravenously at a monthly equivalent dose of about 36 mg.
- ~~110.~~—The method of claim 103, wherein elazakizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- ~~111.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of 5-100 mg.
- ~~112.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 5 mg.
- ~~113.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
- ~~114.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
- ~~115.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 40 mg.
- ~~116.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 60 mg.
- ~~117.~~—The method of claim 103, wherein elazakizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- ~~118.~~—The method of claim 42, wherein the anti-IL-6 antibody is olokizumab.
- ~~119.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of 1.8-60 mg.
- ~~120.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 1.8 mg.
- ~~121.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 3.6 mg.

- ~~122.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 9 mg.
- ~~123.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 18 mg.
- ~~124.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 45 mg.
- ~~125.~~—The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- ~~126.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of 3-100 mg.
- ~~127.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 3 mg.
- ~~128.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 6 mg.
- ~~129.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 15 mg.
- ~~130.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 30 mg.
- ~~131.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 72 mg.
- ~~132.~~—The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- ~~133.~~—The method of claim 42, wherein the anti-IL-6 antibody is VX30 (VOP-R003; Vaccinex).
- ~~134.~~—The method of claim 133, wherein VX30 (VOP-R003; Vaccinex) is administered intravenously.
- ~~135.~~—The method of claim 133, wherein VX30 (VOP-R003; Vaccinex) is administered subcutaneously.
- ~~136.~~—The method of claim 42, wherein the anti-IL-6 antibody is EB-007 (EBI-029; Eleven-Bio).

- ~~137.~~—The method of claim 136, wherein EB 007 (EBI 029; Eleven Bio) is administered intravenously.
- ~~138.~~—The method of claim 136, wherein EB 007 (EBI 029; Eleven Bio) is administered subcutaneously.
- ~~139.~~—The method of claim 42, wherein the anti IL 6 antibody is FM101 (Femta Pharmaceuticals, Lonza).
- ~~140.~~—The method of claim 139, wherein FM101 (Femta Pharmaceuticals, Lonza) is administered intravenously.
- ~~141.~~—The method of claim 139, wherein FM101 (Femta Pharmaceuticals, Lonza) is administered subcutaneously.
- ~~142.~~—The method of any one of claims 1 to 41, wherein the IL 6 antagonist is an anti IL 6R antibody.
- ~~143.~~—The method of claim 142, wherein the anti IL 6R antibody is tocilizumab.
- ~~144.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of 50-500 mg.
- ~~145.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 50 mg.
- ~~146.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 100 mg.
- ~~147.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 150 mg.
- ~~148.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 250 mg.
- ~~149.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 350 mg.
- ~~150.~~—The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 500 mg.
- ~~151.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of 80-800 mg.

- ~~152.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
- ~~153.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 160 mg.
- ~~154.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 240 mg.
- ~~155.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 400 mg.
- ~~156.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 560 mg.
- ~~157.~~—The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 800 mg.
- ~~158.~~—The method of claim 142, wherein the anti-IL-6R antibody is sarilumab.
- ~~159.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of 12-120 mg.
- ~~160.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 12 mg.
- ~~161.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 24 mg.
- ~~162.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 48 mg.
- ~~163.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- ~~164.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 72 mg.
- ~~165.~~—The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 120 mg.
- ~~166.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of 20-200 mg.

- ~~167.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
- ~~168.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 40 mg.
- ~~169.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
- ~~170.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- ~~171.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 120 mg.
- ~~172.~~—The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 200 mg.
- ~~173.~~—The method of claim 142, wherein the anti-IL-6R antibody is vobarilizumab.
- ~~174.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of 4-120 mg.
- ~~175.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 4 mg.
- ~~176.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 6 mg.
- ~~177.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 30 mg.
- ~~178.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- ~~179.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 84 mg.
- ~~180.~~—The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 120 mg.
- ~~181.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of 7-200 mg.

- ~~182.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 7 mg.
- ~~183.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
- ~~184.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 50 mg.
- ~~185.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- ~~186.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 140 mg.
- ~~187.~~—The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 200 mg.
- ~~188.~~—The method of any one of claims 1 to 41, wherein the IL-6 antagonist is a JAK-inhibitor.
- ~~189.~~—The method of any one of claims 1 to 41, wherein the IL-6 antagonist is a STAT3-inhibitor.
- ~~190.~~—The method of any of the above claims, wherein the patient has a hepcidin-mediated disorder.
- ~~191.~~—The method of any one of claims 1 to 189, wherein the patient has kidney disease.
- ~~192.~~—The method of claim 191, wherein the patient has chronic kidney disease.
- ~~193.~~—The method of claim 192, wherein the patient has KDOQI stage 1-5 chronic kidney disease.
- ~~194.~~—The method of claim 193, wherein the patient has KDOQI stage 3-5 chronic kidney disease.
- ~~195.~~—The method of claim 194, wherein the patient is not on dialysis.
- ~~196.~~—The method of claim 193, wherein the patient has KDOQI stage 5 chronic kidney disease.
- ~~197.~~—The method of claim 196, wherein the patient is on dialysis.
- ~~198.~~—The method of claim 192, wherein the patient has cardiorenal syndrome (CRS).

- ~~199.~~—The method of claim 198, wherein the patient has CRS Type 4.
- ~~200.~~—The method of any one of claims 1 to 189, wherein the patient has cardiovascular disease.
- ~~201.~~—The method of claim 200, wherein the patient has diuretic resistant heart failure.
- ~~202.~~—The method of claim 200, wherein the patient has congestive heart failure (CHF).
- ~~203.~~—The method of claim 202, wherein the patient has congestive heart failure (CHF) with reduced ejection fraction.
- ~~204.~~—The method of claim 202, wherein the patient has congestive heart failure (CHF) with mid range ejection fraction.
- ~~205.~~—The method of claim 202, wherein the patient has congestive heart failure (CHF) with preserved ejection fraction.
- ~~206.~~—The method of claim 200, wherein the patient has acute coronary syndrome.
- ~~207.~~—The method of claim 200, wherein the patient has atherosclerosis.
- ~~208.~~—The method of any one of claims 1 to 189, wherein the patient has anemia.
- ~~209.~~—The method of claim 208, wherein the patient has anemia of chronic disease.
- ~~210.~~—The method of claim 208, wherein the patient has iron refractory iron deficiency anemia (IRIDA).
- ~~211.~~—The method of any one of claims 1 to 189, wherein the patient has diabetes.
- ~~212.~~—The method of claim 211, wherein the patient has type II diabetes.
- ~~213.~~—The method of claim 211, wherein the patient has insulin resistant diabetes.
- ~~214.~~—The method of any one of claims 1 to 189, wherein the patient has liver disease.
- ~~215.~~—The method of claim 214, wherein the patient has non alcoholic steatohepatitis (NASH).
- ~~216.~~—The method of any one of claims 1 to 189, wherein the patient has osteoporosis.
- ~~217.~~—The method of any one of claims 1 to 189, wherein the patient has depression.
- ~~218.~~—The method of any one of claims 1 to 189, wherein the patient has asthma.
- ~~219.~~—The method of any one of claims 1 to 189, wherein the patient has neuroinflammatory disorder.

- ~~220.~~—The method of claim 219, wherein the patient has Alzheimer's disease.
- ~~221.~~—The method of claim 219, wherein the patient has Parkinson's disease.
- ~~222.~~—The method of claim 219, wherein the patient has multiple sclerosis.
- ~~223.~~—The method of claim 219, wherein the patient has amyotrophic lateral sclerosis (ALS).
- ~~224.~~—The method of any one of claims 1 to 189, wherein the patient has age-related macular degeneration (AMD).
- ~~225.~~—The method of any one of claims 1 to 189, wherein the patient has cancer.
- ~~226.~~—The method of claim 225, wherein the cancer is selected from the group consisting of: solid tumors, small cell lung cancer, non-small cell lung cancer, hematological cancer, multiple myeloma, leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), lymphomas, Hodgkin's lymphoma and hepatic adenoma.
- ~~227.~~—The method of any one of claims 1 to 189, wherein the patient has skin disease.
- ~~228.~~—The method of any one of claims 1 to 189, wherein the method prevents aging in the patient.
- ~~229.~~—A method for treating inflammation in a patient with cardiovascular disease, comprising:
- ~~administering an IL-6 antagonist to a patient with cardiovascular disease and CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.~~
- ~~230.~~—The method of claim 229, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- ~~231.~~—The method of claim 230, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- ~~232.~~—The method of claim 231, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

~~233.~~—A method for treating inflammation in a patient with chronic kidney disease (CKD), comprising:

~~administering an IL-6 antagonist to a patient with CKD and a CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.~~

~~234.~~—The method of claim 233, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

~~235.~~—The method of claim 234, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

~~236.~~—The method of claim 235, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.